The Insides Company

09/07/2025

When little Isabella was born at just 30 weeks, her whānau faced a terrifying journey that is incredibly hard for any parents to walk. Fortunately, The Insides Neo was able to help, and Isabella not only survived but is now thriving.
We are deeply grateful to Danielle and Andrew for bravely sharing their story. Your courage will help so many other families facing similar challenges.
A heartfelt thank you to Cure Kids for funding the research that made this innovation possible, and to Cure Kids Ventures for enabling The Insides to take this life-changing technology to the world.
To the extraordinary team at the Auckland Hospital NICU and Starship Foundation - thank you for your tireless dedication, skill, and compassion. You are true heroes.
Read the full story below from the Eastern Bays Courier (June 25, 2025) below to see how this Kiwi innovation is changing lives.

https://www.pressreader.com/new-zealand/eastern-bays-courier/20250625/page/1

Eastern Bays Courier

03/07/2025

The Insides Company expands into Greece through an exclusive partnership with Medella S.A.
We’re pleased to announce the appointment of Medella S.A., based in Athens, as our exclusive distribution partner in Greece.
With two decades of experience in clinical nutrition, Medella is well-positioned to introduce chyme reinfusion therapy (CRT) to healthcare professionals across the country. Together, we aim to improve outcomes for patients with intestinal failure, supporting nutritional status and restoring gut function with The Insides System.
This collaboration represents a key milestone as we continue to make CRT available for all patients in Europe.

25/06/2025

The Insides Company supports Stomal Therapy Week 2025 (23–29 June) in collaboration with NZ and Australian stomal therapy nurses. This year’s theme, Ostomateship, celebrates the connection between ostomates and their supporters.

15/06/2025

This week, The Insides Company joins with GBUK Group!
Our colleague Mark Harvie will showcase how The Insides System uses Chyme Reinfusion Therapy to support nutrition pathways, reduce PN dependence & improve patient outcomes.
Let’s connect!

09/06/2025

The Insides System was featured at the 43rd ACOI Congress in Rimini, June 1–4. Our partner Innovamedica presented the latest innovations in intestinal failure management, including Chyme Reinfusion Therapy, in the Innovation Room.

22/05/2025

The Insides Company has appointed Tutku Saglik Gerecleri Tic. A.S as our exclusive distributor in Türkiye, further expanding access to Chyme Reinfusion Therapy for patients with intestinal failure.

With Tutku’s strong presence in the surgical community, this partnership will help deliver innovative solutions that support better patient outcomes across the region.

Read More:
https://www.theinsides.co/news/tutku-saglik-gerecleri-distribution-turkey

12/05/2025

The Insides Company has partnered with Biotech Medical as our exclusive distributor in Qatar, expanding access to chyme reinfusion therapy for patients with intestinal failure across the Middle East.

Find out more:
https://www.theinsides.co/news/biotech-medical

04/05/2025

Chyme Reinfusion Therapy offers a promising solution for patients with intestinal failure caused by conditions like short bowel or enterocutaneous fistulas. While parenteral nutrition is often necessary, it comes with long-term risks and a reduced quality of life. Chyme reinfusion supports gut rehabilitation by restoring nutrient flow to the downstream intestine, improving absorption, and promoting intestinal adaptation.

In a study of over 300 patients, 89% were able to stop intravenous supplementation just one week after starting chyme reinfusion, with many experiencing weight gain and improved nutritional status. This technique empowers patients to regain control over their nutrition and reduce reliance on IV support.

Read More: https://www.theinsides.co/blog/nutrition-in-intestinal-failure

Intestinal failure is defined by the European Society for Clinical Nutrition and Metabolism (ESPEN) as the reduction of gut function below the minimum ...

30/04/2025

Join The Insides Company and our Australian distributor OptiMed Technologies at the RACS Annual Scientific Congress this week in Sydney.
Visit our colleague Emma Ludlow and the OptiMed team at booth 41 from Saturday 3rd to Tuesday 6th May to learn more about how The Insides® System and The Insides® Neo are improving surgical outcomes for patients with intestinal failure through chyme reinfusion therapy.
We’ll also be showcasing the first live demonstration of The Insides® Channel, our latest innovation designed for managing separated stomas and fistulas.
We look forward to engaging with the surgical community and continuing to support innovation in colorectal and gastrointestinal care.

30/04/2025

The Insides Company supports global awareness of Necrotising Enterocolitis (NEC), a rare but serious neonatal disease.

May is NEC Awareness Month. We extend our commendation to organisations such as NEC Society for their leadership in advancing awareness, research, and education around NEC.

Our device, The Insides® Neo, enables Chyme Reinfusion Therapy for neonates with surgical NEC and other conditions that lead to the formation of Double Enterostomies. In a recent feasibility study, four of the patients had surgical NEC and used The Insides Neo. The device dramatically improved weight gain and reduced reliance and weaning of parenteral nutrition.

Read more: https://www.theinsides.co/clinical-publication/evaluating-the-efficacy-and-safety-of-neonatal-chyme-reinfusion-therapy

28/04/2025

Attend the AASTN 2025 Conference to hear Emma Ludlow present "Chyme Reinfusion Therapy across the Lifespan" on Wednesday, 30th April at 3:30 PM at Pullman Melbourne on the Park.
Emma is a leading Chyme Reinfusion Therapy specialist with extensive stomal therapy nursing experience across Australasia and the Middle East. She has contributed to multiple research publications demonstrating the benefits of Chyme reinfusion therapy for intestinal failure patients in both adult and neonatal populations.
We look forward to engaging with the stoma therapy community on advancing clinical practice through innovative therapies.

10/04/2025

For patients recovering from intestinal failure, chyme reinfusion plays a critical role in supporting the safe transition from parenteral nutrition to oral feeding.
In this blog, CNS Stomal Therapist Emma Ludlow outlines the clinical rationale for restarting oral intake, the process involved, and how chyme reinfusion helps restore gut function. The gradual introduction of chyme and oral nutrition supports bowel rehabilitation, reduces complications associated with long-term IV nutrition, and improves patient outcomes.
Read more about how chyme reinfusion facilitates this important step in patient recovery:
https://www.theinsides.co/blog/the-process-of-transitioning-to-oral-feeding

This blog will discuss the process for transitioning from parenteral nutrition to oral feeding when starting chyme reinfusion....